Sartorius Acquires Danaher Life Science Businesses for $750 million

October 24, 2019
BioPharm International Editors

The transaction is set to be completed in the first quarter of 2020.

Sartorius announced it has signed an agreement to acquire parts of Danaher’s Life Science Portfolio for $750 million in cash on Oct. 21, 2019.

According to a press release, the agreement highlights three businesses that are part of the Washington, DC-based science and technology company Danaher Life Science’s portfolio. The businesses include:

  • FortéBio, a label-free biomolecular characterization business that houses protein analysis instruments, biosensors, and reagents for drug discovery, located in Fremont, California and Shanghai, China.

  • The Bioprocess Solutions division, which is comprised of multi-use and single-use equipment and chromatography columns and resins, located in Europe and the United States.

  • SoloHill, a company that uses microcarrier technology and particle validation standards used in cell culture and other bioprocesses, located in Ann Arbor, MI.

Sartorius plans to expand sectors of its business to fit the acquired companies, according to the release.

“The portfolio proposed for acquisition represents an excellent strategic fit with Sartorius,” said Dr. Joachim Kreuzburg, Sartorius’ CEO, in the press release. “With the Octet platform of FortéBio, we will add a broadly accepted and differentiated technology for advancing and simplifying drug discovery to our lab division’s portfolio. The chromatography hardware and resins and the microcarrier businesses broaden our strong bioprocessing offering, particularly in the downstream area. We look very much forward to welcoming the new teams to Sartorius and to jointly combine our capabilities for the benefit of our biopharma and life science customers.”

The transaction is set to be completed in the first quarter of 2020.

Source: Sartorius